دورية أكاديمية
أعرض في EDS

Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.

التفاصيل البيبلوغرافية
العنوان: Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
المؤلفون: Plumb ID; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA. Electronic address: iplumb@cdc.gov., Briggs Hagen M; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA., Wiegand R; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA., Dumyati G; University of Rochester Medical Center, Rochester, NY, USA., Myers C; University of Rochester Medical Center, Rochester, NY, USA., Harland KK; University of Iowa, Iowa City, IA, USA., Krishnadasan A; Olive View- UCLA Education and Research Institute, CA, USA., James Gist J; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA., Abedi G; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA., Fleming-Dutra KE; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA., Chea N; National Center for Emerging and Zoonotic Diseases, Centers for Disease Control & Prevention, USA., Lee JE; California Emerging Infections Program, Oakland, CA, USA., Kellogg M; Colorado Department of Public Health & Environment, CO, USA., Edmundson A; Connecticut Emerging Infections Program, Yale School of Public Health, CT, USA., Britton A; Georgia Emerging Infections Program and Emory University School of Medicine, Atlanta, GA, USA., Wilson LE; Maryland Emerging Infections Program, Maryland Department of Health and University of Maryland, Baltimore, MD, USA., Lovett SA; Minnesota Department of Health, MN, USA., Ocampo V; Public Health Division, Oregon Health Authority, OR, USA., Markus TM; Vanderbilt University Medical Center, Nashville, TN, USA., Smithline HA; Baystate Medical Center, Springfield, MA, USA., Hou PC; Brigham and Women's Hospital, Boston, MA, USA., Lee LC; Jackson Memorial Hospital, Miami, FL, USA., Mower W; David Geffen School of Medicine, UCLA, CA, USA., Rwamwejo F; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Steele MT; University of Missouri-Kansas City, Kansas City, MO, USA., Lim SC; University Medical Center New Orleans, LSU Health Sciences Center, New Orleans, LA, USA., Schrading WA; University of Alabama at Birmingham, Birmingham, AL, USA., Chinnock B; University of California San Francisco, Fresno, CA, USA., Beiser DG; University of Chicago, Chicago, IL, USA., Faine B; University of Iowa, Iowa City, IA, USA., Haran JP; University of Massachusetts Chan Medical School, Worcester, MA, USA., Nandi U; University of Mississippi Medical Center, Jackson, MS, USA., Chipman AK; University of Washington, Seattle, WA, USA., LoVecchio F; Valleywise Health Medical Center, Phoenix, AZ, USA., Eucker S; Duke University School of Medicine, NC, USA., Femling J; University of New Mexico Health Science Center, USA., Fuller M; University of Utah School of Medicine, USA., Rothman RE; Department of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA., Curlin ME; Oregon Health and Sciences University, USA., Talan DA; David Geffen School of Medicine, UCLA, CA, USA., Mohr NM; University of Iowa, Iowa City, IA, USA.
مؤلفون مشاركون: Vaccine Effectiveness among Healthcare Personnel Study Team
المصدر: Vaccine [Vaccine] 2024 Apr 11; Vol. 42 (10), pp. 2543-2552. Date of Electronic Publication: 2023 Nov 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
مواضيع طبية MeSH: COVID-19*/prevention & control, Humans ; Infant, Newborn ; COVID-19 Vaccines ; Vaccines, Combined ; mRNA Vaccines ; Case-Control Studies ; SARS-CoV-2 ; RNA, Messenger ; Delivery of Health Care
مستخلص: Background: Bivalent mRNA vaccines were recommended since September 2022. However, coverage with a recent vaccine dose has been limited, and there are few robust estimates of bivalent VE against symptomatic SARS-CoV-2 infection (COVID-19). We estimated VE of a bivalent mRNA vaccine dose against COVID-19 among eligible U.S. healthcare personnel who had previously received monovalent mRNA vaccine doses.
Methods: We conducted a case-control study in 22 U.S. states, and enrolled healthcare personnel with COVID-19 (case-participants) or without COVID-19 (control-participants) during September 2022-May 2023. Participants were considered eligible for a bivalent mRNA dose if they had received 2-4 monovalent (ancestral-strain) mRNA vaccine doses, and were ≥67 days after the most recent vaccine dose. We estimated VE of a bivalent mRNA dose using conditional logistic regression, accounting for matching by region and four-week calendar period. We adjusted estimates for age group, sex, race and ethnicity, educational level, underlying health conditions, community COVID-19 exposure, prior SARS-CoV-2 infection, and days since the last monovalent mRNA dose.
Results: Among 3,647 healthcare personnel, 1,528 were included as case-participants and 2,119 as control-participants. Participants received their last monovalent mRNA dose a median of 404 days previously; 1,234 (33.8%) also received a bivalent mRNA dose a median of 93 days previously. Overall, VE of a bivalent dose was 34.1% (95% CI, 22.6%-43.9%) against COVID-19 and was similar by product, days since last monovalent dose, number of prior doses, age group, and presence of underlying health conditions. However, VE declined from 54.8% (95% CI, 40.7%-65.6%) after 7-59 days to 21.6% (95% CI 5.6%-34.9%) after ≥60 days.
Conclusions: Bivalent mRNA COVID-19 vaccines initially conferred approximately 55% protection against COVID-19 among U.S. healthcare personnel. However, protection waned after two months. These findings indicate moderate initial protection against symptomatic SARS-CoV-2 infection by remaining up-to-date with COVID-19 vaccines.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Monica Brackney owned stock in Moderna from November 2022–April 2023 stock as part of portfolio managed by Parametric Investments Portfolio LLC. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.].
(Published by Elsevier Ltd.)
References: Trends Immunol. 2021 Nov;42(11):956-959. (PMID: 34580004)
JAMA. 2022 Feb 15;327(7):619-620. (PMID: 35072715)
BMJ. 2023 Jul 25;382:e075286. (PMID: 37491022)
EBioMedicine. 2023 Sep;95:104734. (PMID: 37515986)
BMJ Med. 2023 Feb 1;2(1):e000385. (PMID: 36936268)
Nat Med. 2023 Mar;29(3):574-578. (PMID: 36864253)
Nat Commun. 2023 Mar 24;14(1):1633. (PMID: 36964146)
MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441. (PMID: 36355612)
N Engl J Med. 2022 Mar 10;386(10):933-941. (PMID: 35020982)
Euro Surveill. 2023 Feb;28(7):. (PMID: 36795500)
Nat Med. 2022 May;28(5):1063-1071. (PMID: 35189624)
N Engl J Med. 2023 Jan 12;388(2):183-185. (PMID: 36546661)
Lancet Infect Dis. 2023 May;23(5):556-567. (PMID: 36681084)
Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. (PMID: 37274183)
Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601)
MMWR Morb Mortal Wkly Rep. 2023 Jan 20;72(3):73-75. (PMID: 36656784)
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705. (PMID: 33760236)
Vaccine. 2023 Mar 10;41(11):1783-1790. (PMID: 36774332)
MMWR Morb Mortal Wkly Rep. 2023 Feb 10;72(6):145-152. (PMID: 36757865)
J Infect Dis. 2023 Jun 15;227(12):1348-1363. (PMID: 36806690)
N Engl J Med. 2022 Sep 15;387(11):1011-1020. (PMID: 36044620)
Lancet Infect Dis. 2022 Sep;22(9):1293-1302. (PMID: 35753318)
Sci Transl Med. 2023 Mar 22;15(688):eadg2783. (PMID: 36947596)
Nat Rev Immunol. 2021 Jun;21(6):395-404. (PMID: 33927374)
Lancet Infect Dis. 2022 Dec;22(12):1663-1665. (PMID: 36306800)
J Travel Med. 2023 Sep 5;30(5):. (PMID: 37555656)
Nat Commun. 2023 Sep 20;14(1):5851. (PMID: 37730701)
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1625-1630. (PMID: 36580424)
Nat Commun. 2022 Feb 3;13(1):671. (PMID: 35115517)
Science. 2022 Mar 11;375(6585):1116-1121. (PMID: 35271324)
MMWR Morb Mortal Wkly Rep. 2022 Dec 02;71(48):1526-1530. (PMID: 36454688)
MMWR Morb Mortal Wkly Rep. 2023 Feb 03;72(5):119-124. (PMID: 36730051)
Lancet. 2023 Mar 11;401(10379):833-842. (PMID: 36930674)
Am J Epidemiol. 2023 Feb 24;192(3):328-333. (PMID: 36446573)
J Clin Epidemiol. 2015 Apr;68(4):470-4. (PMID: 25662008)
JAMA. 2021 Mar 9;325(10):998-999. (PMID: 33566056)
N Engl J Med. 2021 Dec 16;385(25):e90. (PMID: 34551224)
MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):651-656. (PMID: 37319011)
Prev Med Rep. 2022 Aug;28:101857. (PMID: 35706687)
N Engl J Med. 2023 May 11;388(19):1818-1820. (PMID: 37043647)
Open Forum Infect Dis. 2023 Sep 08;10(10):ofad457. (PMID: 37799130)
Nat Commun. 2022 Mar 4;13(1):1162. (PMID: 35246536)
Epidemiology. 2021 Jul 1;32(4):508-517. (PMID: 34001753)
Epidemiology. 2020 Nov;31(6):836-843. (PMID: 32841988)
Epidemiology. 2019 Nov;30(6):838-844. (PMID: 31430265)
Nat Rev Microbiol. 2023 Mar;21(3):162-177. (PMID: 36653446)
Science. 2022 Jul 15;377(6603):eabq1841. (PMID: 35699621)
MMWR Morb Mortal Wkly Rep. 2023 May 26;72(21):579-588. (PMID: 37227984)
معلومات مُعتمدة: CC999999 United States ImCDC Intramural CDC HHS; U01 CK000643 United States CK NCEZID CDC HHS; U01CK000480 United States ACL ACL HHS; UL1 TR002537 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: Bivalent; COVID-19; COVID-19 vaccines; Healthcare personnel; SARS-CoV-2; Vaccine effectiveness; mRNA vaccines
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Vaccines, Combined)
0 (mRNA Vaccines)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20231116 Date Completed: 20240408 Latest Revision: 20240409
رمز التحديث: 20240409
مُعرف محوري في PubMed: PMC10994739
DOI: 10.1016/j.vaccine.2023.10.072
PMID: 37973512
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-2518
DOI:10.1016/j.vaccine.2023.10.072